{"downloaded": true, "htmlmade": false, "full": {"id": "30016963", "source": "MED", "pmid": "30016963", "pmcid": "PMC6050722", "fullTextIdList": {"fullTextId": "PMC6050722"}, "doi": "10.1186/s12967-018-1579-3", "title": "Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens.", "authorString": "Chen P, Zhu KW, Zhang DY, Yan H, Liu H, Liu YL, Cao S, Zhou G, Zeng H, Chen SP, Zhao XL, Yang J, Chen XP.", "authorList": {"author": [{"fullName": "Chen P", "firstName": "Peng", "lastName": "Chen", "initials": "P", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China."}, {"affiliation": "Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, Hunan, People's Republic of China."}]}}, {"fullName": "Zhu KW", "firstName": "Ke-Wei", "lastName": "Zhu", "initials": "KW", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China."}, {"affiliation": "Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, Hunan, People's Republic of China."}]}}, {"fullName": "Zhang DY", "firstName": "Dao-Yu", "lastName": "Zhang", "initials": "DY", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China."}, {"affiliation": "Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, Hunan, People's Republic of China."}]}}, {"fullName": "Yan H", "firstName": "Han", "lastName": "Yan", "initials": "H", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China."}, {"affiliation": "Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, Hunan, People's Republic of China."}]}}, {"fullName": "Liu H", "firstName": "Han", "lastName": "Liu", "initials": "H", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China."}, {"affiliation": "Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, Hunan, People's Republic of China."}]}}, {"fullName": "Liu YL", "firstName": "Yan-Ling", "lastName": "Liu", "initials": "YL", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China."}, {"affiliation": "Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, Hunan, People's Republic of China."}]}}, {"fullName": "Cao S", "firstName": "Shan", "lastName": "Cao", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China."}, {"affiliation": "Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, Hunan, People's Republic of China."}]}}, {"fullName": "Zhou G", "firstName": "Gan", "lastName": "Zhou", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China."}, {"affiliation": "Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, Hunan, People's Republic of China."}]}}, {"fullName": "Zeng H", "firstName": "Hui", "lastName": "Zeng", "initials": "H", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China."}}}, {"fullName": "Chen SP", "firstName": "Shu-Ping", "lastName": "Chen", "initials": "SP", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China."}}}, {"fullName": "Zhao XL", "firstName": "Xie-Lan", "lastName": "Zhao", "initials": "XL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China."}}}, {"fullName": "Yang J", "firstName": "Jing", "lastName": "Yang", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, People's Republic of China."}}}, {"fullName": "Chen XP", "firstName": "Xiao-Ping", "lastName": "Chen", "initials": "XP", "authorId": {"@type": "ORCID", "#text": "0000-0002-4956-8727"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China. chenxp74@hotmail.com."}, {"affiliation": "Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, Hunan, People's Republic of China. chenxp74@hotmail.com."}, {"affiliation": "National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China. chenxp74@hotmail.com."}]}}]}, "authorIdList": {"authorId": {"@type": "ORCID", "#text": "0000-0002-4956-8727"}}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "1", "volume": "16", "journalIssueId": "2701916", "dateOfPublication": "2018 Jul", "monthOfPublication": "7", "yearOfPublication": "2018", "printPublicationDate": "2018-07-01", "journal": {"title": "Journal of translational medicine", "ISOAbbreviation": "J Transl Med", "medlineAbbreviation": "J Transl Med", "NLMid": "101190741", "ISSN": "1479-5876", "ESSN": "1479-5876"}}, "pubYear": "2018", "pageInfo": "197", "abstractText": "<h4>Backgrounds</h4>UDP-glucuronosyltransferase 1A subfamily (UGT1A) enzymes can inactivate cytarabine (Ara-C) by glucuronidation, and thus serves as candidate genes for interindividual difference in Ara-C response. UGT1A1 is a major UGT1A isoform expressed in human liver.<h4>Methods</h4>UGT1A1*6 and *28 polymorphisms resulting in reduced UGT1A1 activity were genotyped in 726 adult acute myeloid leukemia (AML) patients treated with Ara-C based regimens. Influences of both polymorphisms on chemosensitivity and disease prognosis of the patients were evaluated.<h4>Results</h4>After one or two courses of Ara-C based induction chemotherapy, the complete remission (CR) rate was significantly higher in patients carrying the UGT1A1*6 (77.0%) or the UGT1A1*28 (76.4%) alleles as compared with corresponding wild-type homozygotes (66.9 and 68.5%, respectively). Carriers of the UGT1A1*6 or *28 alleles showed significantly decreased risk of non-CR (OR\u2009=\u20090.528, 95% CI 0.379-0.737, P\u2009=\u20091.7\u2009\u00d7\u200910<sup>-4</sup>) and better overall survival (HR\u2009=\u20090.787, 95% CI 0.627-0.990, P\u2009=\u20090.040) as compared with homozygotes for both polymorphisms.<h4>Conclusion</h4>Our results suggest that UGT1A1*28 and UGT1A1*6 are associated with improved clinical outcomes in Chinese AML patients treated with Ara-C.", "affiliation": "Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China.", "publicationStatus": "epublish", "language": "eng", "pubModel": "Electronic", "pubTypeList": {"pubType": ["Clinical Trial", "Research Support, Non-U.S. Gov't", "research-article", "Journal Article"]}, "grantsList": {"grant": [{"grantId": "No.2016L04", "agency": "Clinical Research Foundation of Xiangya Hospital", "orderIn": "0"}, {"grantId": "No.81673518", "agency": "National Natural Science Foundation of China", "orderIn": "0"}, {"grantId": "No. 2017YFC0909302", "agency": "National key R&amp;D program", "orderIn": "0"}, {"grantId": "No.81422052", "agency": "National Natural Science Foundation of China", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Glucuronosyltransferase", "meshQualifierList": {"meshQualifier": {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Cytarabine", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Prognosis"}, {"majorTopic_YN": "N", "descriptorName": "Treatment Outcome"}, {"majorTopic_YN": "N", "descriptorName": "Remission Induction"}, {"majorTopic_YN": "N", "descriptorName": "Multivariate Analysis"}, {"majorTopic_YN": "N", "descriptorName": "Proportional Hazards Models"}, {"majorTopic_YN": "N", "descriptorName": "Risk Factors"}, {"majorTopic_YN": "N", "descriptorName": "Follow-Up Studies"}, {"majorTopic_YN": "N", "descriptorName": "Polymorphism, Single Nucleotide", "meshQualifierList": {"meshQualifier": {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Leukemia, Myeloid, Acute", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "EN", "qualifierName": "enzymology", "majorTopic_YN": "N"}, {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Genetic Association Studies"}]}, "keywordList": {"keyword": ["Polymorphism", "Acute Myeloid Leukemia (Aml)", "Cytarabine (Ara-c)", "Udp-glucuronosyltransferase Family 1 Member A1 (Ugt1a1)"]}, "chemicalList": {"chemical": [{"name": "Glucuronosyltransferase", "registryNumber": "EC 2.4.1.17"}, {"name": "Cytarabine", "registryNumber": "04079A1RDZ"}, {"name": "UGT1A1 enzyme", "registryNumber": "EC 2.4.1.-"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1186/s12967-018-1579-3"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6050722"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6050722?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "4", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "refsnp"}, "dateOfCompletion": "2019-06-19", "dateOfCreation": "2018-07-19", "firstIndexDate": "2018-07-19", "fullTextReceivedDate": "2020-07-11", "dateOfRevision": "2019-06-19", "electronicPublicationDate": "2018-07-17", "firstPublicationDate": "2018-07-17"}, "htmllinks": "https://europepmc.org/articles/PMC6050722", "abstract": "<h4>Backgrounds</h4>UDP-glucuronosyltransferase 1A subfamily (UGT1A) enzymes can inactivate cytarabine (Ara-C) by glucuronidation, and thus serves as candidate genes for interindividual difference in Ara-C response. UGT1A1 is a major UGT1A isoform expressed in human liver.<h4>Methods</h4>UGT1A1*6 and *28 polymorphisms resulting in reduced UGT1A1 activity were genotyped in 726 adult acute myeloid leukemia (AML) patients treated with Ara-C based regimens. Influences of both polymorphisms on chemosensitivity and disease prognosis of the patients were evaluated.<h4>Results</h4>After one or two courses of Ara-C based induction chemotherapy, the complete remission (CR) rate was significantly higher in patients carrying the UGT1A1*6 (77.0%) or the UGT1A1*28 (76.4%) alleles as compared with corresponding wild-type homozygotes (66.9 and 68.5%, respectively). Carriers of the UGT1A1*6 or *28 alleles showed significantly decreased risk of non-CR (OR\u2009=\u20090.528, 95% CI 0.379-0.737, P\u2009=\u20091.7\u2009\u00d7\u200910<sup>-4</sup>) and better overall survival (HR\u2009=\u20090.787, 95% CI 0.627-0.990, P\u2009=\u20090.040) as compared with homozygotes for both polymorphisms.<h4>Conclusion</h4>Our results suggest that UGT1A1*28 and UGT1A1*6 are associated with improved clinical outcomes in Chinese AML patients treated with Ara-C.", "Keywords": ["Polymorphism", "Acute Myeloid Leukemia (Aml)", "Cytarabine (Ara-c)", "Udp-glucuronosyltransferase Family 1 Member A1 (Ugt1a1)"], "pdflinks": "https://europepmc.org/articles/PMC6050722?pdf=render", "journaltitle": "Journal of translational medicine", "authorinfo": ["Chen P", "Zhu KW", "Zhang DY", "Yan H", "Liu H", "Liu YL", "Cao S", "Zhou G", "Zeng H", "Chen SP", "Zhao XL", "Yang J", "Chen XP"], "title": "Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens."}